Pharma stocks have outperformed with YTD return of -0.1% vs -10.85% for Nifty. EquityMaster has picked 4 stocks with promoter holding > 50%, RoE > 14% & track record of consistent profitability. These are Torrent Pharma, Divis, Zydus life & Ajanta Pharma
Pharma Stocks Show Resilience Amid Market Volatility: 4 Picks to Watch
In a year marked by volatility in the Indian equity markets, the pharmaceutical sector has emerged as a relative outperformer. While the broader benchmark index has faced significant pressure, pharma stocks have demonstrated resilience, reinforcing their reputation as a defensive investment segment.
Pharma vs Nifty: A Stark Contrast
Year-to-date (YTD), the Nifty Pharma Index has remained nearly flat with a marginal return of -0.1%, compared to a sharp decline of -10.85% in the Nifty 50.
This divergence highlights the sector’s stability during uncertain times. Pharma companies typically benefit from consistent demand for healthcare products, making them less sensitive to economic cycles compared to other industries.
Why Pharma Stocks Are Holding Up
Several structural and market-driven factors explain this outperformance:
- Defensive nature: Demand for medicines remains steady regardless of economic conditions
- Global diversification: Many Indian pharma companies derive revenue from international markets
- Sector rotation: Investors often shift to safer sectors like pharma during market downturns
- Long-term growth drivers: Rising healthcare needs and aging populations continue to support the industry
Equitymaster’s Stock Selection Criteria
Investment research platform Equitymaster has identified four pharma stocks that stand out based on strong fundamentals. The selection criteria include:
- Promoter holding greater than 50%
- Return on Equity (RoE) above 14%
- Consistent track record of profitability
Top 4 Pharma Stocks to Watch
Based on these parameters, the following companies have been highlighted:
1. Torrent Pharmaceuticals
A leading player in chronic therapies such as cardiovascular and central nervous system treatments, Torrent Pharma benefits from strong domestic presence and strategic acquisitions. The company also maintains high promoter holding and robust profitability metrics.
2. Divi’s Laboratories
A globally recognized manufacturer of active pharmaceutical ingredients (APIs), Divi’s has built a strong reputation for operational efficiency and export-driven growth.
3. Zydus Lifesciences
With a diversified portfolio spanning formulations, APIs, and wellness products, Zydus combines innovation with global expansion. The company also boasts strong promoter confidence and healthy returns.
4. Ajanta Pharma
Focused on specialty and branded generics, Ajanta Pharma has demonstrated consistent growth backed by strong R&D capabilities and expanding presence in emerging markets.
The Bigger Picture
The pharma sector continues to offer a compelling mix of stability and growth. While it may not always deliver high short-term returns, its ability to protect capital during downturns makes it an important component of a balanced portfolio.
However, investors should remain selective. Factors such as regulatory risks, pricing pressures, and R&D effectiveness play a crucial role in long-term performance. Companies with strong balance sheets, consistent earnings, and niche product portfolios are better positioned to outperform.
Conclusion
In an otherwise challenging market environment, pharma stocks have proven their defensive strength. With solid fundamentals and long-term growth drivers intact, the sector remains an attractive space for investors seeking stability along with steady returns.
